ArticleEuropean journal of clinical pharmacology2026
Physiologically based pharmacokinetic modeling of cefotaxime to inform pediatric dosing in renal impairment.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCefotaxime (CFT) is a broad spectrum, third-generation cephalosporin antibiotic prescribed for the treatment of severe infections, yet dosing guidelines for pediatric with renal impairment is scarce. The current study aimed to develop a physiological based pharmacokinetic (PBPK) model to characterize CFT disposition and model-based recommend dose adjustments in pediatrics with renal impairment.
methodsInitially, the PBPK model of CFT was developed in adults with normal renal function before being scaled to pediatrics, considering age-related physiological changes using GastroPlus® software. Renal impairment was modelled through optimization of tubular secretion and glomerular filtration parameters based on observed data for both adults and pediatric populations.
resultsThe model reasonably reproduced the observed pharmacokinetic profiles and showed acceptable agreement with the data (fold error ranges 0.84-1.37) or with renal impairment (fold error ranges 0.87-1.12). When compared to children with normal renal function, the predicted AUC0-∞ in children with renal impairment increased to 1.22- and 1.89-fold for moderate and severe renal impairment, respectively. Model-informed dose recommendations were 60% and 48% of the standard pediatric dose for moderate and severe renal impairment, respectively.
conclusionThis PBPK framework supports rational, model-informed dosing of CFT in pediatric patients with varying renal impairment and supports dose recommendation development for high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.